StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM – Free Report) in a research note released on Wednesday. The brokerage issued a sell rating on the stock.
CEL-SCI Stock Performance
CEL-SCI stock opened at $0.43 on Wednesday. CEL-SCI has a fifty-two week low of $0.36 and a fifty-two week high of $3.08. The company has a market capitalization of $31.46 million, a PE ratio of -0.73 and a beta of 0.65. The company has a 50 day moving average price of $0.62 and a 200-day moving average price of $0.95. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64.
Hedge Funds Weigh In On CEL-SCI
Large investors have recently bought and sold shares of the business. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI in the third quarter valued at approximately $98,000. Thoroughbred Financial Services LLC boosted its position in shares of CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after purchasing an additional 80,001 shares in the last quarter. Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares during the last quarter. Calton & Associates Inc. acquired a new position in CEL-SCI during the 3rd quarter valued at about $50,000. Finally, Renaissance Technologies LLC raised its stake in CEL-SCI by 29.9% in the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after buying an additional 40,000 shares during the last quarter. Institutional investors own 12.08% of the company’s stock.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Read More
- Five stocks we like better than CEL-SCI
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Do ETFs Pay Dividends? What You Need to Know
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.
